✦ LIBER ✦

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study

✍ Scribed by Borje S Andersson; Ashwin Kashyap; Victor Gian; John R Wingard; Hugo Fernandez; Pablo J Cagnoni; Roy B Jones; Stefano Tarantolo; Wendy W Hu; Karl G Blume; Stephen J Forman; Richard E Champlin

Book ID: 117816209
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 162 KB
Volume: 8
Category: Article
ISSN: 1083-8791
DOI: 10.1053/bbmt.2002.v8.pm11939604

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thiotepa and fractionated TBI conditioni

Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial

✍ Devetten, M P; Qazilbash, M H; Beall, C L; Bunner, P; Weisenborn, R; Lynch, J P; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 127 KB

Non-Myeloablative (NMA) Allogeneic Hemat

Non-Myeloablative (NMA) Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation (Bu/Flu/TBI) Conditioining: Results of a Phase II Trial

✍ Brammer, Jonathan E.; Stentz, Alex; Dibb, James; Frires, Rachel; Meyers, Gabriel 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB

CD34+ Cell Dose and Full Donor Chimerism

CD34+ Cell Dose and Full Donor Chimerism at Day +100 Is Associated with Survival in Patients Who Received Reduced-Intensity Conditioning (RIC) With Fludarabine/Melphalan Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies

✍ S.G. Holtan; W.J. Hogan; M.A. Elliott; D.A. Gastineau; T.G. Call; S.A. Ansell; D 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Phase 2 study of targeted intravenous bu

Phase 2 study of targeted intravenous busulfan (IV BU) combined with fractionated total body irradiation (FTBI) and etoposide (VP-16) as preparative regimen for allogeneic peripheral blood stem cell transplant (PBSCT) for patients with poor risk leukemia

✍ A.S. Stein; M.R. O’Donnell; A. Dagis; A. Krishnan; A. Nademanee; R. Nakamura; P. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

229: Twice-Daily Intravenous (IV) Busulf

229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults

✍ I. Waxman; M. Bhatia; M. Milone; L.M. Shaw; L. Baldinger; O. Militano; J. Garvin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB